Home Orsiro From BIOTRONIK, Industry's First Hybrid Drug-Eluting Stent, Performs As Best In Class
 

Keywords :   


Orsiro From BIOTRONIK, Industry's First Hybrid Drug-Eluting Stent, Performs As Best In Class

2013-06-05 07:26:54| drugdiscoveryonline News Articles

Primary end-point results from the BIOFLOW-II Clinical Study demonstrating the non-inferiority of the BIOTRONIK Orsiro Hybrid Drug-Eluting Stent compared to Abbott's XIENCE PRIME™

Tags: in class hybrid performs

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
07.10House prices close to record high, says Halifax
07.10Hurricane Milton Public Advisory Number 7A
07.10Summary for Hurricane Milton (AT4/AL142024)
07.10Atlantic Tropical Weather Outlook
07.10Eastern North Pacific Tropical Weather Outlook
07.10Hurricane Milton Potential Storm Surge Flooding Map
07.10Hurricane Milton Probabilistic Storm Surge Graphics
07.10Hurricane Milton Graphics
More »